Wegovy® (semaglutide injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea. Wegovy® should not be used in combination with any other semaglutide-containing drug (e.g., Ozempic®, Rybelsus®) or any other GLP-1 receptor agonist.

Wegovy® is indicated in pediatric patients aged 12 to less than 18 years with an initial BMI at the 95th percentile or greater for age and sex (see Table 1 below), a body weight above 60 kg (132 lbs), and an inadequate response to reduced-calorie diet and physical activity alone.

Table 1: Body mass index (BMI) cut-off points for obesity by sex and age for patients aged 12 to less than 18 years

Please consult the Product Monograph at https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-product-monograph.pdf or click here for more information on:

• Contraindications in patients with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and patients who are pregnant or breastfeeding.
• A serious warning on risk of thyroid C-cell tumours.
• Other relevant warnings and precautions regarding cardiovascular effects (increased heart rate, PR interval prolongation, and use in heart failure), hypoglycemia (precaution with driving and operating machinery), gastrointestinal events, acute pancreatitis, acute gallbladder disease, hypersensitivity/allergy, retinal disorders in patients with type 2 diabetes (monitor in patients with a history of disease), suicidal behaviour and ideation, acute kidney injury, reproductive health (contraception use recommended), and hepatic and renal insufficiency.
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.